$BVAXF News

Last published 2y ago

2y agoBVAXFBioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024GlobeNewswireVANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") a clinical-stage company developing a portfolio of
3y agoBVAXF FRABioVaxys and The Ohio State University Extend Research CollaborationPR NewswireVANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (OTCQB:BVAXF) (5LB: FRA) ("BioVaxys" or "the Company"), is pleased to announce that it has further extended its research
3y agoBVAXFBIOVAXYS ANNOUNCES MANAGEMENT CHANGEPR NewswireVANCOUVER, BC , June 30, 2023 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") regrets to announce that Dasha Enenko has resigned as CFO of the Company to
3y agoBVAXFBIOVAXYS ANNOUNCES SALE OF TAET SOFTWARE COPR NewswireVANCOUVER, BC, June 13, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that it has sold TAET Software Co. to 10402588
3y agoBVAXFBIOVAXYS REPORTS AGM RESULTSPR NewswireVANCOUVER, BC, June 7, 2023 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that the results of its Annual General Meeting held on
3y agoBVAXFBIOVAXYS RETAINS MAXIM GROUP AS FINANCIAL ADVISOR AND INVESTMENT BANKERPR NewswireVANCOUVER, British Columbia, April 17, 2023 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that it has retained New York City-based
3y agoBVAXFBIOVAXYS ANNOUNCES APPOINTMENT OF CFO AND BOARD CHANGESPR NewswireVANCOUVER, BC, April 12, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that Dasha Enenko has been appointed as its
3y agoBVAXFBIOVAXYS ACQUIRES CLINICAL STUDY MANAGEMENT COMPANY AND COMPLETES PRIVATE PLACEMENTPR NewswireVANCOUVER, BC, March 16, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") today announced that it has acquired TAETSoftware Corp
3y agoBVAXFBioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel and Oral ImmunocapsPR NewswireVANCOUVER, British Colombia and BARCELONA, Spain, Dec. 19, 2022 /PRNewswire/ - BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") and Procare Health Iberia, of
3y agoBVAXFBioVaxys Announces Results from The Ohio State University Pan-Sarbecovirus Animal StudyPR NewswireVANCOUVER, BC, Dec. 16, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") announced today that possibly based on the selected study design, results from
3y agoBVAXFBioVaxys Co-Founder, President and Chief Operating Officer Kenneth Kovan to Present at MedInvest Oncology Investor ConferencePR NewswireVANCOUVER, BC, Dec. 5, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that Co-Founder, President & Chief Operating
3y agoBVAXF CTIC IMGN MRK+1Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling HopePR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- The global ovarian cancer market is projected to continue to grow through the coming several years. The formation of mutational cells
3y agoBVAXFBioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer VaccinePR NewswireVANCOUVER, BC, Dec. 1, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce the successful sterile and bacteria-free test-run
3y agoBVAXFBIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENTPR NewswireVANCOUVER, BC, Nov. 28, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV, FRA: 5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") announces that it has closed the first tranche ("Tranche 1") of a
3y agoBVAXFBioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021PR NewswireVANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing
4y agoBVAXFBIOVAXYS ANNOUNCES COMPLETED PRIVATE PLACEMENT AND DEBT SETTLEMENTPR NewswireVANCOUVER, BC, Nov. 10, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") announces that it has completed a non-brokered private placement (the
4y agoBVAXFBIOVAXYS ANNOUNCES DEBT SETTLEMENTPR NewswireVANCOUVER, BC, Oct. 27, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") announces that it has agreed to settle an aggregate of $150,000 in debt
4y agoBVAXFBIOVAXYS ANNOUNCES DEBT SETTLEMENTPR NewswireVANCOUVER, BC, Oct. 6, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") announces that it has agreed to settle an aggregate of $300,000 in debt
4y agoBVAXFBioVaxys Further Expands Vaccines Intellectual Property PortfolioPR NewswireVANCOUVER, BC, Sept. 28, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") announced today that in an action that further expands the value of their IP portfolio, the Company has broadened the p
4y agoBVAXFBIOVAXYS CLOSES FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENTPR NewswireVANCOUVER, BC, Sept. 19, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV, FRA: 5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of its previously announced non-brokered privat
4y agoBVAXFBioVaxys Announces New Chief Financial OfficerPR NewswireVANCOUVER, BC, Sept. 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Craig Loverock has joined the Company as Chief Financial Officer. Mr. Loverock is replacin
4y agoBVAXFBioVaxys announces completed synthesis of its Pan-Sarbecovirus Vaccine candidate and launch of in vivo animal studyPR NewswireVANCOUVER, BC, Sept. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") announced today that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has complete
4y agoBVAXFBIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENTPR NewswireVANCOUVER, BC, Aug. 26, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche ("Tranche 1") of its previously announced non-brokered pr
4y agoBVAXFBIOVAXYS ANNOUNCES WARRANT EXTENSIONPR NewswireVANCOUVER, BC, Aug. 9, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV, FRA: 5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") announces that it has extended the expiry date of 4,483,689 share purchase warrants with an exercise price of $0.50 and
4y agoBVAXFBIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENTPR NewswireVANCOUVER, British Columbia, Aug. 4, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement") consisting of up to 10,000,00
4y agoBVAXFBIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENTPR NewswireVANCOUVER, B.C., Aug. 2, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") further to its news release dated July 4, 2022, BioVaxys announces that it has settled an aggregate of $517,854 in debt th
4y agoBVAXFBIOVAXYS ANNOUNCES PROPOSED DEBT SETTLEMENTPR NewswireVANCOUVER, B.C., July 4, 2022 /CNW/ - BioVaxys Technology Corp. (CSE:BIOV, FRA: 5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") announces that is proposing to settle an aggregate of approximately $497,000 in debt through the issuance of common shares to
4y agoBVAXFClinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process DevelopmentPR NewswireVANCOUVER, BC, June 15, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils de Lyon in France ("HCL") has surgically excised th
4y agoBVAXFBio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical StudyPR NewswireVANCOUVER, BC, June 8, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that its Lyon, France-based bioproduction partner, BioElpida ("BioElpida"), has completed the creation of
4y agoBVAXFBioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research ProgramPR NewswirePan-Sarbecovirus Vaccines Identified by WHO as a Critical Need VANCOUVER, BC, June 3, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") announced today that The Ohio State University ("Ohio
4y agoBMY BVAXF CLSN IMGN+1Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer ProgressionPR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 18, 2022 /PRNewswire/ -- Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30 years, researchers have been looking
4y agoBVAXFBioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply AgreementPR NewswireVANCOUVER, BC, May 18, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV, FRA: 5LB, OTCQB: BVAXF))) ("BioVaxys" or "Company"), announced today that Hospices Civils de Lyon, France ("HCL") has agreed to serve as a clinical study site for the Phase
4y agoBVAXFInternational Patent Application Filed for Cervical Cancer VaccinePR NewswireVANCOUVER, BC, May 2, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has continued to expand the patent coverage for its cancer vaccine platform by filing an internat
4y agoBVAXFBIOVAXYS ANNOUNCES APPOINTMENT TO BOARD OF DIRECTORSPR NewswireVANCOUVER, BC , April 29, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV, FRA: 5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Anthony Dutton has been appointed as a director of the Company. Anthony is cu
4y agoBVAXFBioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 BioproductionPR NewswireVANCOUVER, BC, April 25, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement with the Deaconess Research Institute ("DRI") to supply BioVaxy
4y agoBVAXF CLVS CTIC IMGN+1Advanced Immunological and Clinical Trials for Treating Ovarian Cancer AcceleratingPR NewswirePALM BEACH, Fla., April 25, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer remains undetected until the mutation spre
4y agoBVAXFBioVaxys Expands Cancer Vaccine PlatformPR NewswireBVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC, March 30, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA: 5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer
4y agoBNTX BVAXF MRNA PFE+1Race to Develop Universal 'Variant-Proof' Covid Vaccine Involves Several PlayersPR NewswireVANCOUVER, BC, March 24, 2022 /PRNewswire/ -- USA News Group - Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight back with other than more restrictions or boosters of authorized shots such as those from
4y agoBVAXFBioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State UniversityPR NewswireVANCOUVER, BC, March 17, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement with Millipore-Sigma ("Millipore") a global Contract Development
4y agoBVAXFBioVaxys Closes Final Tranche of Non-brokered Private PlacementPR NewswireVANCOUVER, BC, Feb. 28, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the second and final tranche (the "Final Tranche") of its previously ann
4y agoBVAXF BVAXBIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 proteinPR NewswireSUGGESTS superior cardiAC safety compared to mRNA AND ADENOVIRUS VECTOR vaccines VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-
4y agoBVAXFBIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENTPR NewswireVANCOUVER, BC, Feb. 10, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche ("Tranche 1") of its previously announced non-brokered private
4y agoBVAXFBIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENTPR NewswireVANCOUVER, BC, Feb. 8, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA: 5LB), (OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement") consisting of up to 6,666,667 uni
4y agoBNTX BVAXF MRNA NVAX+1Biotech Sector's Response to Omicron Panic Should be Swift and EffectivePR NewswireVANCOUVER, BC, Dec. 7, 2021 /PRNewswire/ -- USA News Group - Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts, the market's reaction to the latest COVID-19 variant scare (omicron) has been swift. A multitude of react
4y agoBVAXF GSK JNJ RDHL+1Anxious World Waits As Covid Vaccine Makers Address Omicron VariantPR NewswirePALM BEACH, Fla., Dec. 7, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - There are many unknowns surrounding the new omicron Covid variant; there are early signs it's more transmissible, but it's not yet known what risks it poses to publi
4y agoBVAXF LMNGFBiovaxys Announces Major Research Collaboration With The Ohio State University To Develop Broadly Reactive Pan-Sarbecovirus VaccinePR NewswireVANCOUVER, BC, Dec. 7, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company"), a clinical-stage immunotherapy company developing novel approaches to harness T cells to treat cancer and to detect an
4y agoBVAXF LMNGFBioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine PlatformPR NewswireVANCOUVER, BC, Nov. 18, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA: 5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), a clinical-stage immunotherapy company, is pleased to announce that its Chief Medical Officer David Berd, MD, has
4y agoBVAXF LMNGFBioVaxys Co-Founder and Chief Medical Officer David Berd, MD, to Present at World Vaccine & Immunotherapy Congress West Coast 2021PR NewswireVANCOUVER, BC, Nov. 17, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA: 5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), a clinical-stage immunotherapy company, announced today that Company Co-Founder and Chief Medical Officer David Ber
5y agoABT BDX BVAXF DGX+1Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up AuthorizationsPR NewswireVANCOUVER, B.C., Nov. 9, 2021 /PRNewswire/ -- USA News Group - New at-home Covid tests are on the way, according to the Biden administration, which announced a new $70 million plan to speed up authorization, especially in the wake of a shortage. A st
5y agoBVAXF MRK MRNA PFE+1Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030PR NewswirePALM BEACH, Fla., Nov. 9, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the expansion of the COVID-19 therapeutics m